Enthusiastic analyst comment drives BioSphere price up 40%
This article was originally published in Clinica
BioSphere Medical shares rose 40% last week following a favourable comment from a Salomon Smith Barney analyst as he initiated coverage of the development-stage company. The shares rose nearly $5 to finish last Monday on just over $16.50. The analyst, Phil Nailbone, said that the expected target for the company's shares in a year was around $26.